Advertise
NEWSLETTER
Jupiter Neurosciences doses...
Cerevance reports Solengepr...
AgelessRx introduces GHK-Cu...
ProMIS appoints new chief c...
Shift uses AI virtual cells...
Jupiter Neurosciences doses...
Cerevance reports Solengepr...
AgelessRx introduces GHK-Cu...
ProMIS appoints new chief c...
Shift uses AI virtual cells...
Loyal

Loyal’s big-dog lifespan drug clears third FDA hurdle

Loyal raises $100m as canine longevity drug nears approval

FDA clears safety step for Loyal’s senior dog longevity drug

Loyal receives FDA RXE acceptance & raises $22m in new funding

Loyal lands $45m to advance development of dog life extension drugs

Loyal lands $45m to advance development of dog life extension drugs

'We are so close to the future we want'

‘We are so close to the future we want’

Loyal kicks off dog longevity trial

Loyal launches pivotal dog lifespan extension trial

Loyal gets promising FDA feedback on lifespan extension drug for dogs

Longevity investment bulletin: Remedium Bio, GenSight Biologics, SomaLogic and more

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE

  • $617BN - Annual global revenue by 2045
  • $30BN+ - Invested in under 2 years
  • 3,036 - Therapeutics individually assessed